SGO 2019: Maintenance Rucaparib Effective for All Age Groups in Ovarian Cancer
March 22, 2019 5:00 pmBy Christina Bennett, MS
Rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, was effective as a maintenance therapy across all age groups of patients with recurrent ovarian cancer, according to the results of a post-hoc exploratory analysis of ARIEL3 presented at … Read more